发明名称 |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
摘要 |
Disclosed is a fusion protein having a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin comprising: (a) a naturally occurring human erythropoietin molecule having a cysteine residue proximate to a C terminal thereof; and (b) a human IgG Fc fragment comprising a hinge region, wherein the N terminal of said Fc fragment is linked to said C terminal of said erythropoietin molecule and wherein said Fc fragment is naturally occurring except for a mutation replacing a cysteine residue of said hinge region located nearest said erythropoietin molecule with a non-cysteine residue, whereby the first cysteine residue of said hinge region located nearest said N terminal is spaced at least 17 amino acids apart from said cysteine residue of said erythropoietin molecule. |
申请公布号 |
NZ569702(A) |
申请公布日期 |
2012.03.30 |
申请号 |
NZ20070569702 |
申请日期 |
2007.01.25 |
申请人 |
NOVAGEN HOLDING CORPORATION |
发明人 |
WANG, HAITAO;DU, YONG;ZHANG, RUI;XU, JING;LIU, LONGBIN |
分类号 |
C07K14/505;A61K38/18;A61K47/42;A61K47/48;A61P7/00;C07K16/18;C07K19/00;C12N15/13;C12N15/18;C12N15/62;C12P21/02 |
主分类号 |
C07K14/505 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|